Guthart and Gallagher grace Aragon board
This article was originally published in Scrip
Leo Guthart, CEO of Topspin and founder and former CEO of Renaissance Technologies, has joined small-molecule drug discovery company Aragon Pharmaceuticals' board of directors following a $42 million series C financing round by Aragon in which Topspin was a lead investor (scripintelligence.com, 6 March 2012). In addition, Dr Carol Gallagher, previously president and CEO of Calistoga Pharmaceuticals before its acquisition by Gilead Sciences in April 2011, has joined the Aragon board as an independent director.
You may also be interested in...
Almirall has launched its irritable bowel syndrome drug Constella (linaclotide) in six European countries, with several other launches planned for later this year.
Dermira, a dermatology-focused biotech, has raised $35m in a series B financing.
Clovis Oncology has raised its public offering, announced 11 June, from $170m to $240m.